FR2985429B1 - PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS - Google Patents

PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS

Info

Publication number
FR2985429B1
FR2985429B1 FR1250224A FR1250224A FR2985429B1 FR 2985429 B1 FR2985429 B1 FR 2985429B1 FR 1250224 A FR1250224 A FR 1250224A FR 1250224 A FR1250224 A FR 1250224A FR 2985429 B1 FR2985429 B1 FR 2985429B1
Authority
FR
France
Prior art keywords
polymerization process
injectable solution
controlled polymerization
basic insulin
polyaminoacid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1250224A
Other languages
French (fr)
Other versions
FR2985429A1 (en
Inventor
Olivier Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1250224A priority Critical patent/FR2985429B1/en
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to PCT/FR2013/050043 priority patent/WO2013104861A1/en
Priority to CN201380009297.1A priority patent/CN104114155B/en
Priority to EP13701849.5A priority patent/EP2814461B1/en
Priority to BR112014016889A priority patent/BR112014016889A8/en
Priority to CN201710727572.3A priority patent/CN107583039A/en
Priority to CN202111083637.8A priority patent/CN113730555A/en
Priority to US13/737,353 priority patent/US9198971B2/en
Publication of FR2985429A1 publication Critical patent/FR2985429A1/en
Priority to US14/922,663 priority patent/US10335489B2/en
Application granted granted Critical
Publication of FR2985429B1 publication Critical patent/FR2985429B1/en
Priority to HK18108633.6A priority patent/HK1248607A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1250224A 2012-01-09 2012-01-09 PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS Expired - Fee Related FR2985429B1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1250224A FR2985429B1 (en) 2012-01-09 2012-01-09 PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS
US13/737,353 US9198971B2 (en) 2012-01-09 2013-01-09 Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
EP13701849.5A EP2814461B1 (en) 2012-01-09 2013-01-09 Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid)
BR112014016889A BR112014016889A8 (en) 2012-01-09 2013-01-09 composition in the form of an aqueous injectable solution ph is comprised between 6.0 and 8.0 and unit dose formulation with ph comprised between 7 and 7.8
CN201710727572.3A CN107583039A (en) 2012-01-09 2013-01-09 PH is 7 and the Injectable solution at least containing the PI basal insulins for being 5.8 to 8.5 and substitution copolymerization (amino acid)
CN202111083637.8A CN113730555A (en) 2012-01-09 2013-01-09 Injectable solution of basal insulin and substituted copoly (amino acid) having pH7 and at least PI 5.8 to 8.5
PCT/FR2013/050043 WO2013104861A1 (en) 2012-01-09 2013-01-09 Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid)
CN201380009297.1A CN104114155B (en) 2012-01-09 2013-01-09 PH is 7 and includes at least basal insulin and the Injectable solution for being substituted copolymerization (amino acid) that PI is 5.8 to 8.5
US14/922,663 US10335489B2 (en) 2012-01-09 2015-10-26 Injectable solution at pH 7 comprising at least one basal insulin the pi of which is between 5.8 and 8.5 and a substituted co-polyamino acid
HK18108633.6A HK1248607A1 (en) 2012-01-09 2018-07-04 Injectable solution at ph 7 comprising at least one basal insulin the pi of which is between 5.8 and 8.5 and a substituted co-polyamino acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1250224A FR2985429B1 (en) 2012-01-09 2012-01-09 PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS

Publications (2)

Publication Number Publication Date
FR2985429A1 FR2985429A1 (en) 2013-07-12
FR2985429B1 true FR2985429B1 (en) 2016-07-29

Family

ID=46489322

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1250224A Expired - Fee Related FR2985429B1 (en) 2012-01-09 2012-01-09 PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS

Country Status (1)

Country Link
FR (1) FR2985429B1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5950477B2 (en) 2011-08-10 2016-07-13 アドシア Injection solution of at least one basal insulin
CN104114155B (en) 2012-01-09 2019-02-15 阿道恰公司 PH is 7 and includes at least basal insulin and the Injectable solution for being substituted copolymerization (amino acid) that PI is 5.8 to 8.5
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001895B1 (en) * 2013-02-12 2015-07-03 Adocia PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISOELECTRIC POINT IS INCLUDED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
FR3052072A1 (en) 2016-06-07 2017-12-08 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACIDE CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
EP3562500B1 (en) * 2016-12-27 2023-07-19 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a copolyamino acid
FR3074680B1 (en) * 2017-12-07 2020-01-03 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
FR3061023B1 (en) * 2016-12-27 2020-02-28 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
CN111683674A (en) 2017-12-07 2020-09-18 阿道恰公司 Composition in the form of an injectable aqueous solution comprising an amylin, an amylin agonist receptor or an amylin analog and a copoly amino acid
JP2021505607A (en) 2017-12-07 2021-02-18 アドシア An injectable solution at pH 7 containing at least one basal insulin with a pI of 5.8-8.5 and a copolyamino acid with carboxylate charge and hydrophobic radicals.
KR20200106892A (en) 2017-12-07 2020-09-15 아도시아 A solution for injection at pH 7 comprising at least one basal insulin with a pI of 5.8 to 8.5, and a co-polyamino acid bearing a carboxylate charge and a hydrophobic radical
FR3074682B1 (en) * 2017-12-07 2020-01-03 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
WO2019110797A1 (en) * 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2840614B1 (en) * 2002-06-07 2004-08-27 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
EP1567578B1 (en) * 2002-12-04 2008-06-25 Flamel Technologies Polyamino acids functionalized by at least one (oligo)amino acid group and therapeutic uses
FR2862536B1 (en) * 2003-11-21 2007-11-23 Flamel Tech Sa PHARMACEUTICAL FORMULATIONS FOR THE PROLONGED DELIVERY OF ACTIVE (S) PRINCIPLE (S) AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2902007B1 (en) * 2006-06-09 2012-01-13 Flamel Tech Sa PHARMACEUTICAL FORMULATIONS FOR PROLONGED DELIVERY OF ACTIVE (S) PRINCIPLE (S) AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
BRPI0820535B8 (en) * 2007-11-16 2021-05-25 Novo Nordisk As pharmaceutical compositions containing insulin and an insulinotropic peptide
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins

Also Published As

Publication number Publication date
FR2985429A1 (en) 2013-07-12

Similar Documents

Publication Publication Date Title
FR2985429B1 (en) PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS
FR2985428B1 (en) PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACIDE
EP2767314A3 (en) Ball for a ball sport
BR112013006817A2 (en) method, bushing and bushing formed by the method
PH12015502786A1 (en) Method for producing polyimide membranes
FR2997097B1 (en) PROCESS FOR PRODUCING CARBON FIBER, PRECURSOR MATERIAL USED BY THE PROCESS AND CARBON FIBER OBTAINED
SG11201506035SA (en) High-concentration vanadium electrolytic solution, and method and device for producing the same
BR112015029175A2 (en) process for preparing levulinic acid
MX362689B (en) Method for producing 3,5-bis(fluoroalkyl)-pyrazol-4-carboxylic acid derivatives and 3,5-bis(fluoroalkyl)-pyrazoles.
FR3006943B1 (en) METHOD FOR MAKING A FRONT CABLE FOR A VEHICLE, AND FRONT CABLE FOR A VEHICLE OBTAINED BY THIS METHOD.
BR112015020838A2 (en) process for the preparation of polyamides, polyamide and use of a polyamide.
JP2013541099A5 (en)
PL3310636T3 (en) Drive arrangement for a rail vehicle, rail vehicle with a drive arrangement and method for producing the drive arrangement and the rail vehicle
IN2013MU03124A (en)
PL2843261T3 (en) Traction means tensioner, vibration welding device having a traction means tensioner as well as production method for a traction means tensioner.
FR3007031B1 (en) PROCESS FOR THE PREPARATION OF ALKYL LONG CHAINS CYCLIC ACETALS BASED ON SUGAR
LT3433493T (en) Dosing pump for a dosing device, as well as a dosing device
BR112013018974A2 (en) improved process for the preparation of 2,2-difluoroethylamine.
FR3003564B1 (en) METATHESIS METHOD COMPRISING THE EXTRACTION OF ETHYLENE FORMED USING A MEMBRANE
FR3030406B1 (en) ATTACHING A SECURITY BELT REEL TO THE VEHICLE'S MID-LEVEL FOOT, REINFORCED TRANSVERSE.
FR2978918B1 (en) PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH AN IP BETWEEN 5.8 AND 8.5
BR112016021874A2 (en) A process for preparing 3,5-bis (haloalkyl) pyrazole derivatives from α, α-diholoamines and ketimines.
FR3022723B1 (en) METHOD FOR SELECTING AT LEAST ONE ENCODING PARAMETER IN A VIDEO ENCODER UNDER ADDITIONAL REGULARITY CONSTRAINTS
MX2013015418A (en) One piece pump with hinge.
Leuckart Musikalien-Verlags-Katalog FEC Leuckart, Leipzig: alphabetisch-systematisch vollständig bis Ende 1913.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20210905